Document is current
Any future updates will be listed below
-
Authors
Kilvaer, Thomas K.
Førde, Dagny
Paulsen, Erna-Elise
Pedersen, Mona Irene
Lombardi, Ana Paola
Rakaee, Mehrdad
Selven, Hallgeir
Donnem, Tom
Busund, Lill-Tove Rasmussen
Andersen, Sigve
-
Funding
Funding for this research was provided by:
UiT The Arctic University of Norway
- License Information
-
More Information
Article History
Received: 14 August 2025
Accepted: 30 January 2026
First Online: 5 February 2026
Declarations
:
: T.K.K. has received a honorary fee for participation in an advisory board for Sun Pharma, M.R. has received lecture fees from AstraZeneca. All other authors declare no competing interests.
: The study was conducted according to the guidelines of the Declaration of Helsinki, and was approved by the Regional Committee for Medical and Health Research Ethics North (REK Nord, protocol IDs: 2011/2503 and 2011/2151). The need for informed consent was waived by REK Nord due to the retrospective nature of the study. The reporting of clinicopathological variables, survival data and biomarker expression was conducted in accordance with the REMARK guidelines.
